StreetAlpha.app
Home › Stocks › RXRX

Recursion Pharmaceuticals, Inc. (RXRX)

Healthcare
$2.45
▼ −9.93%
LAST CLOSE · NOV 20

Recursion is a Salt Lake City biotech company that uses AI to find and develop medicines for cancer and rare diseases. It last closed at $2.45 on Nov 20, down 9.93% on the day. The next earnings report for RXRX is expected around Wed, Feb 24, 2027. For the quarter ended Sep 2026, RXRX reported EPS of -$0.22 on revenue of $18.6M, with revenue up 258.5% from a year ago. Over its last 8 reports the stock moved an average of 6.0% the session after earnings. Over the last 12 months RXRX insiders bought $0 of stock on the open market and sold $7.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is RXRX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RXRX.

Key Stats

Last 12 months
Results
Revenue
$68.2M
+56.2% vs a year ago
Net income
−$475.7M
−697.1% margin
EPS (diluted)
−$0.86
Free cash flow
−$312.5M
−458.0% margin
Valuation
Market cap
$1.5B
622.8M shares
P/E
–
No P/E while losing money
Price to sales
22.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$549.9M
At Sep 30
Shareholder equity
$905.8M
Shares outstanding
622.8M
At Oct 26
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.2M$10.2MFY2021FY2022: $39.8M$39.8MFY2022FY2023: $44.6M$44.6MFY2023FY2024: $58.8M$58.8MFY2024FY2025: $74.7M$74.7MFY2025

From RXRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · Time not announced
Reported EPS
-$0.22
Quarter ended Sep 2026
Year ago EPS
-$0.36
Same quarter last year
Revenue
$18.6M
+258.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.57Dec '24Mar 2025: -$0.50Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.36Sep '25Dec 2025: -$0.17Dec '25Mar 2026: -$0.22Mar '26Jun 2026: -$0.25Jun '26Sep 2026: -$0.22Sep '26Latest -$0.22
Revenue by quarter
Dec 2024: $4.5MDec '24Mar 2025: $14.7MMar '25Jun 2025: $19.2MJun '25Sep 2025: $5.2MSep '25Dec 2025: $35.5MDec '25Mar 2026: $6.5MMar '26Jun 2026: $7.7MJun '26Sep 2026: $18.6MSep '26Latest $18.6M
How RXRX moved after its last 8 reports
Average move the session after a report ±6.0%
Oct 15, 2026Time not announced+11.2%
Aug 5, 2026Time not announced−4.2%
May 6, 2026Time not announced+1.8%
Feb 25, 2026Time not announced+6.8%
Nov 5, 2025Time not announced−0.8%
Aug 5, 2025Time not announced−4.7%
May 5, 2025Time not announced−16.6%
Feb 28, 2025Time not announced−2.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RXRXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RXRX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RXRX

Technical Analysis

RXRX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 43% below its 20 day and 52% below its 50 day average. It is 41% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), oversold. The nearest support is the 52 week low at $2.44, and the nearest resistance the Pivot at $2.55.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.6%/day
Key levels
$5.2452 week high+113.9%
$3.7250 day average+51.8%
$3.51100 day average+43.3%
$3.5020 day average+42.9%
$3.44200 day average+40.4%
$3.13Swing high (Jul 27)+27.8%
$2.66Pivot R1+8.6%
$2.55Pivot+4.1%
$2.45Last close
$2.4452 week low−0.4%
$2.34Pivot S1−4.5%
Indicators
RSI (14)31.04Weak, oversold below 30Neutral
MACD-0.31Below its signal lineBearish
Stochastic11.1Near the bottom of its rangeOversold
ADX (14)24.6Weak trend
Williams %R-99.4Oversold below −80, overbought above −20Oversold
CCI (20)-155.0Oversold below −100, overbought above 100Oversold
Rate of change−30.4%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 13.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RXRX

What happened before

See how RXRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RXRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RXRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RXRXHow many large options trades hit RXRX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RXRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲179 buying vs 155 selling
  • ▲Held by funds +4.2 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 5 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding356351+1.4%
In funds' top 10330.0%
Held by funds62.5%58.2%+4.3 pts
New / increased60 / 11948 / 1310.0%
Reduced / sold out99 / 5699 / 40+11.5%
Put/call ratio1.351.51−10.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RXRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RXRX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$7.4M34 sales · 6 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $2.0M2026-01 sold $1.3M2026-02 sold $1.3M2026-03 sold $840K2026-04 sold $361K2026-05 sold $364K2026-06 sold $368K2026-07 sold $159K2026-08 sold $98K2026-09 sold $179K2026-10 sold $367K2026-11 sold $155KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 3Blake BorgesonDirectorSale plan40,000$3.88$155K
Oct 6Robert HershbergDirectorSale plan25,000$5.00$125K
Oct 6Blake BorgesonDirectorSale plan50,000$4.84$242K
Sep 8Najat KhanCEO and PresidentSale plan22,408$3.52$79K
Sep 1Blake BorgesonDirectorSale plan30,000$3.34$100K
Aug 4Blake BorgesonDirectorSale plan30,000$3.25$98K
Every insider buy and sale for RXRX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RXRX insider trades →

From SEC Form 4 filings by RXRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RXRX is in one of them and how their past RXRX trades turned out.

RXRX in the AI portfolios
Loading…

RXRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RXRX in an article yet. Here's the latest on the wider market.

RXRX in the news

About Recursion Pharmaceuticals

Recursion is a biotechnology company based in Salt Lake City, Utah, that uses artificial intelligence to discover and develop medicines. Its work centers on the Recursion Operating System, a platform that combines biological data, computational molecule design and clinical trial planning. The company develops its own drug candidates, mainly for cancer and rare diseases, and partners with drugmakers such as Roche, Genentech and Sanofi on discovery programs. Its medicines are aimed at patients with serious diseases that have limited treatment options.

Headquarters
Salt Lake City, UT